NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

November 1, 2024

Conditions

Autoimmune DiseasesMultiple Sclerosis

Interventions

DRUG

LPX-TI641

LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Trial Locations (2)

56529

AXIS Clinicals, Dilworth

Unknown

Triumpharma clinical research unit at Alessra Hospital, Amman